Skip to main content
Top
Published in: BMC Infectious Diseases 1/2006

Open Access 01-12-2006 | Research article

Emergence of vancomycin resistant Staphylococcus aureus(VRSA) from a tertiary care hospital from northern part of India

Authors: Hare Krishna Tiwari, Malay Ranjan Sen

Published in: BMC Infectious Diseases | Issue 1/2006

Login to get access

Abstract

Background

Glycopeptides such as vancomycin are frequently the antibiotics of choice for the treatment of infections caused by methicillin resistant Staphylococcus aureus (MRSA). For the last 7 years incidence of vancomycin intermediate S. aureus and vancomycin resistant S. aureus (VISA and VRSA respectively) has been increasing in various parts of the world. The present study was carried out to find out the presence of VISA and VRSA in the northern part of India.

Methods

A total 1681 staphylococcal isolates consisting of 783 S. aureus and 898 coagulase negative staphylococci (CoNS) were isolated from different clinical specimens from various outpatient departments and wards. All S. aureus and 93 CoNS were subjected to MIC testing (against vancomycin, teicolplanin and oxacillin); Brain Heart Infusion (BHI) vancomycin screen agar test; disc diffusion testing, and PCR for mecA, vanA and vanB genes detection.

Results

Out of 783 S. aureus two S. aureus strains were found to be vancomycin and teicoplanin resistant (one strain with MIC 32 μg/ml and the other strain with MIC 64 μg/ml); six strains of S. aureus have shown to be vancomycin intermediate (two strains with MIC 16 μg/ml and four strains with MIC 8 μg/ml); and two strains with teicoplanin intermediate (MIC 16 μg/ml). One CoNS strain was resistant to vancomycin and teicoplanin (MIC 32 μg/ml), and two CoNS strains were intermediate to vancomycin and teicoplanin (MIC 16 μg/ml). All VRSA, VISA and vancomycin resistant CoNS had shown growth on BHI vancomycin screen agar (vancomycin 6 μg/ml) and were mecA PCR positive. None of these isolates have demonstrated vanA/vanB gene by PCR.

Conclusion

The present study reveals for the first time emergence of VISA/VRSA from this part of world and indicates the magnitude of antibiotic resistance in and around the study area. The major cause of this may be unawareness and indiscriminate use of broad-spectrum antibiotics.
Literature
1.
go back to reference Lowy FD: Staphylococcus aureus infections. New Engl J Med. 1998, 339: 520-532. 10.1056/NEJM199808203390806.CrossRefPubMed Lowy FD: Staphylococcus aureus infections. New Engl J Med. 1998, 339: 520-532. 10.1056/NEJM199808203390806.CrossRefPubMed
2.
go back to reference Chambers HF: Methicillin resistance in Staphylococci: molecular and biochemical basis and clinical implications. Clin Microbiol Rev. 1997, 10: 781-791.PubMedPubMedCentral Chambers HF: Methicillin resistance in Staphylococci: molecular and biochemical basis and clinical implications. Clin Microbiol Rev. 1997, 10: 781-791.PubMedPubMedCentral
3.
go back to reference Brumfil W, Hamilton-Miller J: Methicillin resistant Staphylococcus aureus. N Engl J Med. 1989, 320: 1188-1196.CrossRef Brumfil W, Hamilton-Miller J: Methicillin resistant Staphylococcus aureus. N Engl J Med. 1989, 320: 1188-1196.CrossRef
4.
go back to reference Ena J, Dick RW, Jones RN, Wenzel RP: The epidemiology of intravenous vacomycin usage in a university hospital: a 10 year study. JAMA. 1993, 269: 598-602. 10.1001/jama.269.5.598.CrossRefPubMed Ena J, Dick RW, Jones RN, Wenzel RP: The epidemiology of intravenous vacomycin usage in a university hospital: a 10 year study. JAMA. 1993, 269: 598-602. 10.1001/jama.269.5.598.CrossRefPubMed
6.
go back to reference Tenover FC, Biddle JW, Lancaster MV: Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Inf Dis. 2001, 7: 327-332.CrossRef Tenover FC, Biddle JW, Lancaster MV: Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Inf Dis. 2001, 7: 327-332.CrossRef
7.
go back to reference Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC: Methicillin resistant Staphylococcus aureus clinicalstrain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997, 40: 135-136. 10.1093/jac/40.1.135.CrossRefPubMed Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC: Methicillin resistant Staphylococcus aureus clinicalstrain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997, 40: 135-136. 10.1093/jac/40.1.135.CrossRefPubMed
8.
go back to reference Centers for Disease Control and Prevention: Staphylococcus aureus with reduced susceptibility to vancomycin United States, 1997. Morb Mortal Wkly Rep MMWR. 1997, 46: 765-766. Centers for Disease Control and Prevention: Staphylococcus aureus with reduced susceptibility to vancomycin United States, 1997. Morb Mortal Wkly Rep MMWR. 1997, 46: 765-766.
9.
go back to reference Centers for Disease Control and Prevention: Staphylococcus aureus resistant to vancomycin – United States, 2002. Morb Mortal Wkly Rep MMWR. 2002, 51: 565-567. Centers for Disease Control and Prevention: Staphylococcus aureus resistant to vancomycin – United States, 2002. Morb Mortal Wkly Rep MMWR. 2002, 51: 565-567.
10.
go back to reference Palazzo ICV, Araujo MLC, Darini ALC: First Report of Vancomycin-Resistant Staphylococci Isolated from Healthy Carriers in Brazil. J Clin Microbiol. 2005, 43: 179-185. 10.1128/JCM.43.1.179-185.2005.CrossRefPubMedPubMedCentral Palazzo ICV, Araujo MLC, Darini ALC: First Report of Vancomycin-Resistant Staphylococci Isolated from Healthy Carriers in Brazil. J Clin Microbiol. 2005, 43: 179-185. 10.1128/JCM.43.1.179-185.2005.CrossRefPubMedPubMedCentral
11.
go back to reference Bataineh AB: Resistance of Staphylococcus aureus to Vancomycin in Zarqa, Jordan. Pak J Med Sci. 2006, 22: 144-148. Bataineh AB: Resistance of Staphylococcus aureus to Vancomycin in Zarqa, Jordan. Pak J Med Sci. 2006, 22: 144-148.
12.
go back to reference Smith TL, Pearson LM, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, Tenover FC, Zervos MJ, Band JD, White E, Jarvis WR: Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med. 1999, 340: 493-501. 10.1056/NEJM199902183400701.CrossRefPubMed Smith TL, Pearson LM, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, Tenover FC, Zervos MJ, Band JD, White E, Jarvis WR: Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med. 1999, 340: 493-501. 10.1056/NEJM199902183400701.CrossRefPubMed
13.
go back to reference Rotun SS, McMath V, Schoonmaker DJ, Maupin PS, Tenover FC, Hill BC, Ackman DM: Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis. 1999, 5: 147-149.CrossRefPubMedPubMedCentral Rotun SS, McMath V, Schoonmaker DJ, Maupin PS, Tenover FC, Hill BC, Ackman DM: Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis. 1999, 5: 147-149.CrossRefPubMedPubMedCentral
14.
go back to reference Centers for Disease Control and Prevention: Staphylococcus aureus with reduced susceptibility to vancomycin-Illinois, 1999. Morb Mortal Wkly Rep MMWR. 2000, 48: 1165-1167. Centers for Disease Control and Prevention: Staphylococcus aureus with reduced susceptibility to vancomycin-Illinois, 1999. Morb Mortal Wkly Rep MMWR. 2000, 48: 1165-1167.
15.
go back to reference Ploy MC, Grelaud C, Martin C, de Lumley L, Denis F: Firstclinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet. 1998, 351: 1212-10.1016/S0140-6736(05)79166-2.CrossRefPubMed Ploy MC, Grelaud C, Martin C, de Lumley L, Denis F: Firstclinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet. 1998, 351: 1212-10.1016/S0140-6736(05)79166-2.CrossRefPubMed
16.
go back to reference Howe RA, Bowker KE, Walsh TR, Feest TG, MacGowan AP: Vancomycin-resistant Staphylococcus aureus. Lancet. 1998, 351: 602-10.1016/S0140-6736(05)78597-4.CrossRefPubMed Howe RA, Bowker KE, Walsh TR, Feest TG, MacGowan AP: Vancomycin-resistant Staphylococcus aureus. Lancet. 1998, 351: 602-10.1016/S0140-6736(05)78597-4.CrossRefPubMed
17.
go back to reference Bierbaum G, Fuchs K, Lenz W, Szekat C, Sahl HG: Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany. Eur J Clin Microbiol Infect Dis. 1999, 18: 691-696. 10.1007/s100960050380.CrossRefPubMed Bierbaum G, Fuchs K, Lenz W, Szekat C, Sahl HG: Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany. Eur J Clin Microbiol Infect Dis. 1999, 18: 691-696. 10.1007/s100960050380.CrossRefPubMed
18.
go back to reference Assadullah S, Kakru DK, Thoker MA, Bhat FA, Hussain N, Shah A: Emergence of low level vancomycin resistance in MRSA. Indian J Med Microbiol. 2003, 21: 196-198.PubMed Assadullah S, Kakru DK, Thoker MA, Bhat FA, Hussain N, Shah A: Emergence of low level vancomycin resistance in MRSA. Indian J Med Microbiol. 2003, 21: 196-198.PubMed
19.
go back to reference Baird D: Staphylococcus: cluster forming gram positive cocci. Mackie and McCartney Practical Medical Microbiology. Edited by: Collee JG, Fraser AG, Marmion BP, Simmons A. 1996, New York; Churchill Livingstone, 245-261. 14 Baird D: Staphylococcus: cluster forming gram positive cocci. Mackie and McCartney Practical Medical Microbiology. Edited by: Collee JG, Fraser AG, Marmion BP, Simmons A. 1996, New York; Churchill Livingstone, 245-261. 14
20.
go back to reference National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A5. NCCLS. 2000, Wayne, PA, USA, 5 National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A5. NCCLS. 2000, Wayne, PA, USA, 5
21.
go back to reference Maniatis T, Fritsch EF, Sambrook J: Molecular Cloning: a Laboratory Manual. 1982, Cold Spring Harbor: Cold Spring Harbor Laboratory Press Maniatis T, Fritsch EF, Sambrook J: Molecular Cloning: a Laboratory Manual. 1982, Cold Spring Harbor: Cold Spring Harbor Laboratory Press
22.
go back to reference Geha DJ, Uhl JR, Gustaferro CA, Persing DH: Multiplex PCR for identification of methicillin-resistant staphylococci in the clinical laboratory. J Clin Microbiol. 1994, 32: 1768-1772.PubMedPubMedCentral Geha DJ, Uhl JR, Gustaferro CA, Persing DH: Multiplex PCR for identification of methicillin-resistant staphylococci in the clinical laboratory. J Clin Microbiol. 1994, 32: 1768-1772.PubMedPubMedCentral
23.
go back to reference Clark NC, Cooksey RC, Hill BC, Swenson JM, Tenover FC: Characterization of glycopeptide-resistant enterococci from U. S. hospitals. Antimicob Agents Chemother. 1993, 37: 2311-2317.CrossRef Clark NC, Cooksey RC, Hill BC, Swenson JM, Tenover FC: Characterization of glycopeptide-resistant enterococci from U. S. hospitals. Antimicob Agents Chemother. 1993, 37: 2311-2317.CrossRef
24.
go back to reference Song JH, Hiramatsu K, Suh JY, Ko KS, Ito T, Kapi M, Kiem S, Kim YS, Oh WS, Peck KR, Lee NY, Asian Network for Surveillance of Resistant Pathogens Study Group: Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin. Antimicrob Agents Chemother. 2004, 48: 4926-4928. 10.1128/AAC.48.12.4926-4928.2004.CrossRefPubMedPubMedCentral Song JH, Hiramatsu K, Suh JY, Ko KS, Ito T, Kapi M, Kiem S, Kim YS, Oh WS, Peck KR, Lee NY, Asian Network for Surveillance of Resistant Pathogens Study Group: Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin. Antimicrob Agents Chemother. 2004, 48: 4926-4928. 10.1128/AAC.48.12.4926-4928.2004.CrossRefPubMedPubMedCentral
25.
go back to reference Holloway K: Antimicrobial resistance: the facts. Essential Drug Monitor WHO. 2000, 28&29: 7-8. Holloway K: Antimicrobial resistance: the facts. Essential Drug Monitor WHO. 2000, 28&29: 7-8.
26.
go back to reference Noble WC, Virani Z, Cree RC: Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett. 1992, 72: 195-198. 10.1111/j.1574-6968.1992.tb05089.x.CrossRefPubMed Noble WC, Virani Z, Cree RC: Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett. 1992, 72: 195-198. 10.1111/j.1574-6968.1992.tb05089.x.CrossRefPubMed
27.
go back to reference Showsh SA, De Boever RH, Clewell DB: Vancomycin resistance plasmid in Enterococcus faecalis that encodes sensitivity to a sex pheromone also produced by Staphylococcus aureus. Antimicrob Agents Chemother. 2001, 45: 2177-2178. 10.1128/AAC.45.7.2177-2178.2001.CrossRefPubMedPubMedCentral Showsh SA, De Boever RH, Clewell DB: Vancomycin resistance plasmid in Enterococcus faecalis that encodes sensitivity to a sex pheromone also produced by Staphylococcus aureus. Antimicrob Agents Chemother. 2001, 45: 2177-2178. 10.1128/AAC.45.7.2177-2178.2001.CrossRefPubMedPubMedCentral
28.
go back to reference Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, Daum RS, H Labischinski H, Hiramatsu K: Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemother. 1998, 42: 199-209. 10.1093/jac/42.2.199.CrossRefPubMed Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, Daum RS, H Labischinski H, Hiramatsu K: Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemother. 1998, 42: 199-209. 10.1093/jac/42.2.199.CrossRefPubMed
29.
go back to reference Hanaki H, Labischinski H, Inaba Y, Kondo N, Murakami H, Hiramatsu K: Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50. J Antimicrob Chemother. 1998, 42: 315-320. 10.1093/jac/42.3.315.CrossRefPubMed Hanaki H, Labischinski H, Inaba Y, Kondo N, Murakami H, Hiramatsu K: Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50. J Antimicrob Chemother. 1998, 42: 315-320. 10.1093/jac/42.3.315.CrossRefPubMed
30.
go back to reference Cui L, Murakami H, Kuwahara-Arai K, Hanaki H, Hiramatsu K: Contribution of a thickened cell wall and its gultamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. J Antimicrob Chemother. 2000, 44: 2276-2285. 10.1128/AAC.44.9.2276-2285.2000.CrossRef Cui L, Murakami H, Kuwahara-Arai K, Hanaki H, Hiramatsu K: Contribution of a thickened cell wall and its gultamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. J Antimicrob Chemother. 2000, 44: 2276-2285. 10.1128/AAC.44.9.2276-2285.2000.CrossRef
31.
go back to reference Marchese A, Balistreri G, Tonoli E, Debbia EA, Schito GC: Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital. J Clin Microbiol. 2000, 38: 866-869.PubMedPubMedCentral Marchese A, Balistreri G, Tonoli E, Debbia EA, Schito GC: Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital. J Clin Microbiol. 2000, 38: 866-869.PubMedPubMedCentral
32.
go back to reference Rotun SS, McMath V, Schoonmaker DJ, Maupin PS, Tenover FC, Hill BC, Ackman DM: Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis. 1999, 5: 147-149.CrossRefPubMedPubMedCentral Rotun SS, McMath V, Schoonmaker DJ, Maupin PS, Tenover FC, Hill BC, Ackman DM: Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis. 1999, 5: 147-149.CrossRefPubMedPubMedCentral
33.
go back to reference Hiramatsu K: Vancomycin resistance in staphylococci. Drug Resistance Updates. 1998, 1: 135-150. 10.1016/S1368-7646(98)80029-0.CrossRefPubMed Hiramatsu K: Vancomycin resistance in staphylococci. Drug Resistance Updates. 1998, 1: 135-150. 10.1016/S1368-7646(98)80029-0.CrossRefPubMed
Metadata
Title
Emergence of vancomycin resistant Staphylococcus aureus(VRSA) from a tertiary care hospital from northern part of India
Authors
Hare Krishna Tiwari
Malay Ranjan Sen
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2006
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-6-156

Other articles of this Issue 1/2006

BMC Infectious Diseases 1/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.